Major Advances in Triple-Negative Breast Cancer Treatment Happening in Clinical Trials
DR Len Lichtenfeld MD
Former Deputy Chief Medical Officer for American Cancer Society
“Many still think triple-negative breast cancer is the disease it was as recently as 5 years ago. News bulletin: it is not.
It is detectable, it is treatable, and for some survivable in a way we wouldn’t have dreamed of even recently.
The number of new drugs either approved for treatment or in the pipeline of clinical trials is mind boggling.
We need to ditch the stigma, treat the disease, and make certain everyone with triple-negative breast cancer has access to the best possible care.”
TNBC Breakthrough Immunotherapy-Chemo Combination Trial Results Published in The Lancet September 2020
Absence of invasive cancer shown in 69% of patients in the immunotherapy-chemo combination group
20% more patients in the immunotherapy-chemotherapy group showed absence of invasive cancer
“Patients with cancer treated in clinical trials lived longer”
Penn State Cancer Institute - 2020 study of 12 million patients
TrialJectory matches you with triple-negative breast cancer clinical trials that fit your exact cancer diagnosis.
Possible Advanced Treatments Received in Clinical Trials
Directed against a specific protein or molecule in the cancer
Blocks activity of proteins that keep body from fighting cancer
Chemotherapy or other other treatment taken in together with immunotherapy
Chemicals that kill fast-growing cells in the body
Quality of Life
Improving of symptoms, well-being and quality of life
Know YOUR Options
Empower yourself to take control of your cancer treatment.
AI Decision Assistance
Partner with your oncologist using the help of artificial intelligence.
No Big Pharma Bias
Explore options without the influence of drug company.
100% FREE FOR PATIENTS, LOVED ONES, AND CAREGIVERS
"I 100% would not be in this trial if it wasn’t for TrialJectory"
TREATMENT OPTIONS, FREE
Copyright © 2020 Trialjectory